Today, the Centers for Medicare and Medicaid Services (CMS) released the proposed decision memo for the National Coverage Analysis (NCA) for CAR T-cell therapy. The proposal, found here, articulates how CMS would cover the advanced cancer therapy.
We are in the process of reviewing the proposal and will be sending a second communication with a brief summary and draft talking points that can be utilized in your individual or organization’s response. ASBMT and other interested organizations have 30 days to review and comment. CMS will issue final decision no later than 60 days after the conclusion of the 30-day comment period.
ASBMT will be developing its own response and it is imperative that other stakeholders provide meaningful responses during the comment period. Please note that ASBMT submitted comments when CMS initiated the coverage process and participated in the MEDCAC last summer. Our previous comments can be found online here.
Please watch for future communications on this topic and do not hesitate to contact us at email@example.com with any questions that you might have.